Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-[alpha]-negative breast cancer

Background:Although the androgen receptor (AR) is frequently expressed in breast cancer, its relevance in the disease is not fully understood. In addition, the relevance of AR in determining tamoxifen treatment efficiency requires evaluation.Purpose:To investigate the tamoxifen predictive relevance...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2016-02, Vol.114 (3), p.248
Main Authors: Hilborn, Erik, Gacic, Jelena, nander, Tommy, Nordenskjöld, Bo, Stål, Olle, Jansson, Agneta
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 3
container_start_page 248
container_title British journal of cancer
container_volume 114
creator Hilborn, Erik
Gacic, Jelena
nander, Tommy
Nordenskjöld, Bo
Stål, Olle
Jansson, Agneta
description Background:Although the androgen receptor (AR) is frequently expressed in breast cancer, its relevance in the disease is not fully understood. In addition, the relevance of AR in determining tamoxifen treatment efficiency requires evaluation.Purpose:To investigate the tamoxifen predictive relevance of the AR protein expression in breast cancer.MethodsPatients were randomised to tamoxifen 40 mg daily for 2 or 5 years or to no endocrine treatment. Mean follow-up was 15 years. Hazard ratios were calculated with recurrence-free survival as end point.Results:In patients with oestrogen receptor (ER)-negative tumours, expression of AR predicted decreased recurrence rate with tamoxifen (hazard ratio (HR)=0.34; 95% confidence interval (CI)=0.14-0.81; P=0.015), whereas the opposite was seen in the AR- group (HR=2.92; 95% CI=1.16-7.31; P=0.022). Interaction test was significant P
doi_str_mv 10.1038/bjc.2015.464
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1762021133</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3940626411</sourcerecordid><originalsourceid>FETCH-proquest_journals_17620211333</originalsourceid><addsrcrecordid>eNqNjM1OwzAQhK0KpIafWx9gJc4Oa7tt0iNCIB6AG0KV426Ko2C7Xhfl8YkQF26cZkYz8wmxUlgrNO19N7hao9rU6-16ISq1MVqqVjcXokLERuJO41JcMQ9z3GHbVGJ6CIccjxQgk6NUYgaaUiZmHwPM5uBdYegoUO-dtyMU-xkn3_88OMXABD5AJC5_OfLNjunDvstAR1v8F0GXyXIBZ4OjfCMuezsy3f7qtbh7fnp9fJEpx9N5pu2HeM5hrvaq2WrUShlj_rf6Bmy3VTw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1762021133</pqid></control><display><type>article</type><title>Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-[alpha]-negative breast cancer</title><source>PubMed Central</source><creator>Hilborn, Erik ; Gacic, Jelena ; nander, Tommy ; Nordenskjöld, Bo ; Stål, Olle ; Jansson, Agneta</creator><creatorcontrib>Hilborn, Erik ; Gacic, Jelena ; nander, Tommy ; Nordenskjöld, Bo ; Stål, Olle ; Jansson, Agneta</creatorcontrib><description>Background:Although the androgen receptor (AR) is frequently expressed in breast cancer, its relevance in the disease is not fully understood. In addition, the relevance of AR in determining tamoxifen treatment efficiency requires evaluation.Purpose:To investigate the tamoxifen predictive relevance of the AR protein expression in breast cancer.MethodsPatients were randomised to tamoxifen 40 mg daily for 2 or 5 years or to no endocrine treatment. Mean follow-up was 15 years. Hazard ratios were calculated with recurrence-free survival as end point.Results:In patients with oestrogen receptor (ER)-negative tumours, expression of AR predicted decreased recurrence rate with tamoxifen (hazard ratio (HR)=0.34; 95% confidence interval (CI)=0.14-0.81; P=0.015), whereas the opposite was seen in the AR- group (HR=2.92; 95% CI=1.16-7.31; P=0.022). Interaction test was significant P&lt;0.001. Patients with triple-negative and AR+ tumours benefitted from tamoxifen treatment (HR=0.12; 95% CI=0.014-0.95 P=0.044), whereas patients with AR- tumours had worse outcome when treated with tamoxifen (HR=3.98; 95% CI=1.32-12.03; P=0.014). Interaction test was significant P=0.003. Patients with ER+ tumours showed benefit from tamoxifen treatment regardless of AR expression.Conclusions:AR can predict tamoxifen treatment benefit in patients with ER- tumours and triple-negative breast cancer.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2015.464</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group</publisher><ispartof>British journal of cancer, 2016-02, Vol.114 (3), p.248</ispartof><rights>Copyright Nature Publishing Group Feb 2, 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Hilborn, Erik</creatorcontrib><creatorcontrib>Gacic, Jelena</creatorcontrib><creatorcontrib>nander, Tommy</creatorcontrib><creatorcontrib>Nordenskjöld, Bo</creatorcontrib><creatorcontrib>Stål, Olle</creatorcontrib><creatorcontrib>Jansson, Agneta</creatorcontrib><title>Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-[alpha]-negative breast cancer</title><title>British journal of cancer</title><description>Background:Although the androgen receptor (AR) is frequently expressed in breast cancer, its relevance in the disease is not fully understood. In addition, the relevance of AR in determining tamoxifen treatment efficiency requires evaluation.Purpose:To investigate the tamoxifen predictive relevance of the AR protein expression in breast cancer.MethodsPatients were randomised to tamoxifen 40 mg daily for 2 or 5 years or to no endocrine treatment. Mean follow-up was 15 years. Hazard ratios were calculated with recurrence-free survival as end point.Results:In patients with oestrogen receptor (ER)-negative tumours, expression of AR predicted decreased recurrence rate with tamoxifen (hazard ratio (HR)=0.34; 95% confidence interval (CI)=0.14-0.81; P=0.015), whereas the opposite was seen in the AR- group (HR=2.92; 95% CI=1.16-7.31; P=0.022). Interaction test was significant P&lt;0.001. Patients with triple-negative and AR+ tumours benefitted from tamoxifen treatment (HR=0.12; 95% CI=0.014-0.95 P=0.044), whereas patients with AR- tumours had worse outcome when treated with tamoxifen (HR=3.98; 95% CI=1.32-12.03; P=0.014). Interaction test was significant P=0.003. Patients with ER+ tumours showed benefit from tamoxifen treatment regardless of AR expression.Conclusions:AR can predict tamoxifen treatment benefit in patients with ER- tumours and triple-negative breast cancer.</description><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqNjM1OwzAQhK0KpIafWx9gJc4Oa7tt0iNCIB6AG0KV426Ko2C7Xhfl8YkQF26cZkYz8wmxUlgrNO19N7hao9rU6-16ISq1MVqqVjcXokLERuJO41JcMQ9z3GHbVGJ6CIccjxQgk6NUYgaaUiZmHwPM5uBdYegoUO-dtyMU-xkn3_88OMXABD5AJC5_OfLNjunDvstAR1v8F0GXyXIBZ4OjfCMuezsy3f7qtbh7fnp9fJEpx9N5pu2HeM5hrvaq2WrUShlj_rf6Bmy3VTw</recordid><startdate>20160202</startdate><enddate>20160202</enddate><creator>Hilborn, Erik</creator><creator>Gacic, Jelena</creator><creator>nander, Tommy</creator><creator>Nordenskjöld, Bo</creator><creator>Stål, Olle</creator><creator>Jansson, Agneta</creator><general>Nature Publishing Group</general><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20160202</creationdate><title>Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-[alpha]-negative breast cancer</title><author>Hilborn, Erik ; Gacic, Jelena ; nander, Tommy ; Nordenskjöld, Bo ; Stål, Olle ; Jansson, Agneta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_17620211333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hilborn, Erik</creatorcontrib><creatorcontrib>Gacic, Jelena</creatorcontrib><creatorcontrib>nander, Tommy</creatorcontrib><creatorcontrib>Nordenskjöld, Bo</creatorcontrib><creatorcontrib>Stål, Olle</creatorcontrib><creatorcontrib>Jansson, Agneta</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hilborn, Erik</au><au>Gacic, Jelena</au><au>nander, Tommy</au><au>Nordenskjöld, Bo</au><au>Stål, Olle</au><au>Jansson, Agneta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-[alpha]-negative breast cancer</atitle><jtitle>British journal of cancer</jtitle><date>2016-02-02</date><risdate>2016</risdate><volume>114</volume><issue>3</issue><spage>248</spage><pages>248-</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Background:Although the androgen receptor (AR) is frequently expressed in breast cancer, its relevance in the disease is not fully understood. In addition, the relevance of AR in determining tamoxifen treatment efficiency requires evaluation.Purpose:To investigate the tamoxifen predictive relevance of the AR protein expression in breast cancer.MethodsPatients were randomised to tamoxifen 40 mg daily for 2 or 5 years or to no endocrine treatment. Mean follow-up was 15 years. Hazard ratios were calculated with recurrence-free survival as end point.Results:In patients with oestrogen receptor (ER)-negative tumours, expression of AR predicted decreased recurrence rate with tamoxifen (hazard ratio (HR)=0.34; 95% confidence interval (CI)=0.14-0.81; P=0.015), whereas the opposite was seen in the AR- group (HR=2.92; 95% CI=1.16-7.31; P=0.022). Interaction test was significant P&lt;0.001. Patients with triple-negative and AR+ tumours benefitted from tamoxifen treatment (HR=0.12; 95% CI=0.014-0.95 P=0.044), whereas patients with AR- tumours had worse outcome when treated with tamoxifen (HR=3.98; 95% CI=1.32-12.03; P=0.014). Interaction test was significant P=0.003. Patients with ER+ tumours showed benefit from tamoxifen treatment regardless of AR expression.Conclusions:AR can predict tamoxifen treatment benefit in patients with ER- tumours and triple-negative breast cancer.</abstract><cop>London</cop><pub>Nature Publishing Group</pub><doi>10.1038/bjc.2015.464</doi></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 2016-02, Vol.114 (3), p.248
issn 0007-0920
1532-1827
language eng
recordid cdi_proquest_journals_1762021133
source PubMed Central
title Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-[alpha]-negative breast cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T04%3A47%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Androgen%20receptor%20expression%20predicts%20beneficial%20tamoxifen%20response%20in%20oestrogen%20receptor-%5Balpha%5D-negative%20breast%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Hilborn,%20Erik&rft.date=2016-02-02&rft.volume=114&rft.issue=3&rft.spage=248&rft.pages=248-&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2015.464&rft_dat=%3Cproquest%3E3940626411%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_17620211333%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1762021133&rft_id=info:pmid/&rfr_iscdi=true